IP Library Granted Patent US 9,688,767
Granted Patent B2
US 9,688,767 · App. 14/776,029 · Granted Jun 27, 2017

Method of predicting survival time in myocardial infarction patients by measuring BAFF levels

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,688,767
App. No.
14/776,029
Granted
Jun 27, 2017
Kind
B2
Abstract

The present invention relates to a method for predicting the survival time of a patient suffering from myocardial infarction or the recurrence of a myocardial infarction. The method comprises the steps of i) determining the expression level of BAFF in a sample from the patient, ii) comparing the expression level with a predetermined reference value and iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the predetermined reference value and a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the predetermined reference value.

Claims (8)

1. A method for predicting the survival time of a patient suffering from myocardial infarction or the recurrence of a myocardial infarction in a patient who has suffered from a myocardial infarction and treating said patient, comprising the steps of

i) determining the expression level of B cell activating factor (BAFF) in a sample from said patient,

ii) comparing said expression level with a control value, wherein said control value is based on BAFF levels in a collection of samples from patients suffering from myocardial infarction, or based on BAFF levels in a collection of samples from healthy subjects,

iii) providing a good prognosis of the survival time or a low risk of the recurrence of a myocardial infarction when the expression level is lower than the control value,

or providing a poor prognosis of the survival time or a high risk of the recurrence of a myocardial infarction when the expression level is higher than the control value, and

iv) administering a therapeutically effective amount of an anti-CD20 antibody to said patient when a poor prognosis is provided in step iii), wherein the therapeutically effective amount is sufficient to treat said patient.

2. The method according to claim 1 , wherein the patient is a non-lupic patient.

3. The method according to claim 1 , wherein said sample is selected from the group consisting of blood, plasma, serum, lymph and cardiac tissue.

Assignments (3)
CHANGE OF NAME Recorded May 12, 2022
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 059988/0388 →
MERGER Recorded May 12, 2022
From: UNIVERSITE PARIS DESCARTES
To: UNIVERSITE DE PARIS
Reel/Frame 060044/0856 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 5, 2016
From: MALLAT, ZIAD; TEDGUI, ALAIN; SIMON, TABASSOME; DANCHIN, NICOLAS
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE PARIS DESCARTES; UNIVERSITE PIERRE ET MARIE CURIE - UPMC; ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
Reel/Frame 039349/0394 →